Bristol oral psoriasis med OKd by FDA

 Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years

Pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy of once-daily Sotyktu over placebo and twice-daily Otezla^® (apremilast) in improving skin clearance

Sotyktu has a well-demonstrated safety and tolerability profile based on the POETYK PSO clinical trials

https://www.biospace.com/article/releases/-u-s-food-and-drug-administration-approves-sotyktu-deucravacitinib-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis/